## **David Segal**

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9097755/publications.pdf

Version: 2024-02-01

	1684188	2053705
1,259	5	5
citations	h-index	g-index
5	5	2743
J	3	2/43
docs citations	times ranked	citing authors
	citations 5	1,259 5 citations h-index 5

#	Article	IF	CITATIONS
1	Deep profiling of apoptotic pathways with mass cytometry identifies a synergistic drug combination for killing myeloma cells. Cell Death and Differentiation, 2020, 27, 2217-2233.	11.2	29
2	BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival. Cell Death and Disease, 2019, 10, 342.	6.3	125
3	Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer. Science Translational Medicine, 2017, 9, .	12.4	148
4	Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1. Blood, 2016, 128, 1834-1844.	1.4	127
5	The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature, 2016, 538, 477-482.	27.8	830